Role of T-AYU-HM Premium in Paediatric Patients with Sickle Cell Anaemia: A Retrospective Case Series

Abstract

Background: Sickle cell disease (SCD), a genetic disorder caused by a beta globin chain mutation, has been recognized as influencing public health worldwide. In India, numerous tribal and underdeveloped groups frequently suffer from this medical condition. The present study evaluates the effectiveness and safety of alternative medicines T-AYU-HM Premium among paediatric SCD patients. Methodology: A single-arm retrospective observational case series of 10 sickle cell disease paediatric population were conducted. The proposed study was conducted to clinically evaluate the safety and effectiveness of T-AYU-HM Premium Tablet (300mg) on paediatric individuals. The clinical and vital data of the patients were collected, evaluated, and reported using the SPSS software based on inclusion and exclusion criteria. Results: The study had a majority of male (80%) patients with a mean age of 3.20±1.23 years. The present study also identified consanguinity. It also observed a non-significant improvement in weight (12.04 ± 2.45) compared to the baseline (11.64 ± 2.46). There was also a non-significantly decrease in the pulse rate from baseline. In terms of hematological parameters, no significant change was observed from the baseline. However, there was a substantial decrease in pain-associated clinical parameters among the paediatric population. Conclusion: The present retrospective analysis shows that patients with SCD were significantly improved by the T-AYU-HM Premium treatment, proving both its efficacy and safety, particularly in pain management. However, the current analysis suggests a substantial body of evidence (prospective) to support using herbal-mineral formulations for sickle cell anaemia among paediatric patients.